Deutsche Bank analyst David Hoang initiated coverage of Harmony Biosciences (HRMY) with a Buy rating and $55 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences shares ‘attractive’ at current levels, says H.C. Wainwright
- Harmony Biosciences price target raised to $32 from $31 at BofA
- Harmony Biosciences Projects Strong Revenue Growth for 2025
- Harmony Biosciences sees Q4 revenue $201M, consensus $198.6M
- Harmony Biosciences initiated with a Buy at H.C. Wainwright